Bing

SEARCH HISTORY

Pluristem Therapeutics (NASDAQ:PSTI) traded down 1.064% on Tuesday, hitting $2.325. The stock had a trading volume of 77,610 shares. Pluristem Therapeutics has a 52-week low of $2.28 and a 52-week high of $3.78. The stock’s 50-day moving …
wkrb13.com · 7/22/2015
Pluristem Therapeutics (NASDAQ:PSTI) traded down 1.67% during mid-day trading on Tuesday, hitting $2.35. 178,388 shares of the company’s stock traded hands. Pluristem Therapeutics has a 52 week low of $2.28 and a 52 week high of $3.78. The …
Ticker Report · 7/22/2015
Elsewhere in the regenerative-medicine industry, Benjamin is bullish on Ocata Therapeutics (OCAT - Get Report), a company in the ophthalmology business, whose stock is down 32% year to date, and he also likes Pluristem (PSTI - Get Report), an …
The Street · ByGregg Greenberg · 19 hours ago
Benjamin
More from Bing News
Health care is considered a defensive sector, and large-cap health-care stocks tend to outperform in times of economic uncertainty and stock market turmoil ... to aim for the fences with some biotech penny stocks. Now, when I say "penny stocks," I'm ...
NASDAQ · 6/24/2011
Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> PLURISTEM THERAPEUTICS INC (PSTI): Free Stock Analysis Report CORONADO BIOSCIENCES INC (CNDO): Free Stock Analysis Report GENTIUM SPA …
Yahoo Finance · 1/2/2014
Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced top-line results from its Phase I/II clinical trial testing the safety and efficacy of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury. The trial indicated PLX-PAD cells were ...
StreetInsider · 1/21/2014
These stocks were gaining the most during NASDAQ PRE-MARKET sessions as of Monday, October 6, 2014. Conns Inc. (NASDAQ: CONN) now trades at $35.9, up 9.0 percent in Pre-Market sessions on 14360 total share volume. CONN currently trades …
Fx Pips · 10/6/2014
as well as Pluristem (PSTI), a $185 million Israel-based biotherapeutics company. Shares of Pluristem have fallen 5% so far in 2015, but Benjamin expects a second half turnaround. Another stock Benjamin is positive …
MSN · 1 hour ago
Raymond James Analyst
Gosh, it's hard to see why the company would take exception to a headline like that, but here's how the piece leads off, in case things weren't clear: Pluristem Therapeutics Inc.’s (PSTI) stock doubled in Nasdaq trading from May through September ...
Corante · 11/12/2012
NEW YORK, NY--(Marketwired - Jan 27, 2015) - Pluristem Therapuetics (NASDAQ: PSTI) is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.
marketwired.com · 1/27/2015